Oncotelic Therapeutics (OTC: OTLC) Inks Deal With Mosaic ImmunoEngineering To Sell Clinical-Stage Necroptosis Cancer Therapy Assets
–News Direct– By Faith Ashmore, Benzinga The global retinoblastoma treatment market size was estimated to be $2.62 billion in 2023 and is expected to reach $4.20 billion by 2034 with a CAGR of 4.38% over 2024-2034. Rising incidence of retinoblastoma, early diagnosis and treatment, increasing healthcare expenditure, growing awareness of retinoblastoma treatment options, development of…